FDA grants accelerated approval for AstraZeneca breast cancer treatment
The Food and Drug Administration granted accelerated approval for AstraZeneca’s Etcamah (camizestrant) in combination with a CDK4/6 inhibitor to treat eligible advanced breast cancer patients.